These results were concordant with the study by Harter et al., which showed low rates of PD-L1+ and PD-1+ tumors (1%) and low rates of CD3+ (3%) and CD8+ T-cells (2%) in BM samples from CRC [26]. This evidence concerns the gene CD8A and colorectal carcinoma.